Most of the more than 7000 rare diseases described thus far are still orphan

Vincent Mutel, PhD
Chairman of the Board

Dr. Mutel is a seasoned life science entrepreneur. He is currently co-founder and CEO of Inflamalps S.A., co-founder and chairman of Tauderma S.A. and was co-founder, CEO and vice chairman of Addex Pharmaceuticals Ltd, a company he brought to the public Swiss market, and prior to these assignments he was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd.


Massimo Nobile, PhD

Dr. Nobile is head of Life Sciences initiatives at CimArk. Since 2016, he also acts as CEO of the Swiss Biotech Center, a daughter company of CimArk. Massimo joined CimArk in 2010 with the mission to support innovation and economic development in Life Sciences sectors. Massimo manages the technological incubator BioArk, located in Monthey, and is start-up coach at the The Ark Foundation. Prior to joining CimArk, Massimo was leading the Swiss activities of Opsona Therapeutics Ltd, an Irish drug development company. He was in particular in charge of transferring assets to Opsona and launching a novel drug development program. Massimo also worked at Apoxis S.A. that became Topotarget Switzerland S.A. in 2007, and was involved in several immunomodulatory and anti-inflammatory drug development programs, from the discovery to the pre-clinical phases. Massimo did his PhD thesis at the University of Lausanne, in the laboratory of AIDS immunopathogenesis.


Stephane Demotz, PhD

Stephane Demotz is the co-Founder and Chief Executive Officer of Dorphan S.A. He has over twenty years of professional experience gained in academic institutions and the pharmaceutical industry. He has occupied scientist and manager positions in pharmaceutical and biotechnology companies in Switzerland and abroad, where he conducted the preclinical development of numerous compounds in the areas of immunology, inflammation, cancer and rare orphan diseases. He was a co-founder of Edimer Biotech S.A., which developed a drug candidate for the rare and orphan disease X-linked hypohidrotic ectodermal dysplasia. As a member of the Swiss Sanfilippo Foundation since its inception, he co-founded Dorphan S.A. to develop drug candidates for the treatment of rare orphan lysosomal storage diseases. Dr. Demotz holds a PhD in biochemistry and immunology from the University of Lausanne.


Alexander Klimov

Mr. Klimov holds senior management positions at international energy companies in Ukraine, including UGV, the largest producer of natural gas, and Geo Alliance/Vitol Group, the leading international trading and exploration group. He is responsible for strategic development and investment decisions as Director and Head of Strategy/Investments. During his career, he was instrumental for a number of cross-border Mergers & Acquisitions, transactions and investment projects in Energy, Metals & Mining, Technology and Real Estate. He was previously Investment Director at the EastOne Group, Interpipe, Metinvestholding/SCM Group and New Europe/Ikon Private Equity. He received his BA in International Economics from the Kiev National Economic University, Ukraine.